These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 7086638

  • 1. [The simultaneous determination of Ara-U and Ara-C, urinary metabolites of N4-behenoyl-1-beta-D-arabinofuranosylcytosine by mass fragmentography (author's transl)].
    Makino Y, Matsubara Y, Watanabe K, Hirobe M.
    Yakugaku Zasshi; 1982 Jan; 102(1):49-55. PubMed ID: 7086638
    [No Abstract] [Full Text] [Related]

  • 2. Production of N4-succinyl-1-beta-D-arabinofuranosylcytosine, a novel metabolite of N4-behenoyl-1-beta-D-arabinofuranosylcytosine, in mice and its biological significance.
    Oh-ishi J, Kataoka T, Tsukagoshi S, Sakurai Y, Shibukawa M, Kobayashi H.
    Cancer Res; 1981 Jun; 41(6):2501-6. PubMed ID: 7237444
    [Abstract] [Full Text] [Related]

  • 3. Cytotoxicity of N4-behenoyl-1-beta-D-arabinofuranosylcytosine through gradual conversion to 1-beta-D-arabinofuranosylcytosine in HeLa cells.
    Maehara Y, Kusumoto T, Sakaguchi Y, Kusumoto H, Anai H, Sugimachi K.
    Anticancer Res; 1989 Jun; 9(1):41-4. PubMed ID: 2705754
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia.
    Ueda T, Nakamura T, Ando S, Kagawa D, Sasada M, Uchino H, Johno I, Akiyama Y.
    Cancer Res; 1983 Jul; 43(7):3412-6. PubMed ID: 6850647
    [Abstract] [Full Text] [Related]

  • 5. Metabolism of the new liposomal anticancer drug N4-octadecyl-1-beta-D-arabinofuranosylcytosine in mice.
    Koller-Lucae SK, Suter MJ, Rentsch KM, Schott H, Schwendener RA.
    Drug Metab Dispos; 1999 Mar; 27(3):342-50. PubMed ID: 10064564
    [Abstract] [Full Text] [Related]

  • 6. Intracellular distribution of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in blood cells.
    Ueda T, Nakamura T, Kagawa D, Yamamoto K, Uchida M, Sasada M, Uchino H.
    Gan; 1983 Jun; 74(3):445-51. PubMed ID: 6884702
    [Abstract] [Full Text] [Related]

  • 7. Membrane affinity and metabolism of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine into cultured KB cells.
    Tsuruo T, Iida H, Hori K, Tsukagoshi S, Sakurai Y.
    Cancer Res; 1981 Nov; 41(11 Pt 1):4484-8. PubMed ID: 7306971
    [Abstract] [Full Text] [Related]

  • 8. Clinical pharmacology of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in patients with hematologic malignancies.
    Ueda T, Nakamura T, Kagawa D, Uchida M, Domae N, Sugiyama M, Ueda Y, Sasada M, Uchino H.
    Cancer Chemother Pharmacol; 1989 Nov; 24(6):371-5. PubMed ID: 2791191
    [Abstract] [Full Text] [Related]

  • 9. Plasma and leukemic cell pharmacokinetics of high-dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute leukemia patients.
    Yoshida T, Kobayashi K, Okabe Y, Okumura H, Matano S, Kanno M, Takeda Y, Ohtake S, Nakamura S, Matuda T.
    J Clin Pharmacol; 1994 Jan; 34(1):52-9. PubMed ID: 8132852
    [Abstract] [Full Text] [Related]

  • 10. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
    Hori K, Tsuruo T, Naganuma K, Tsukagoshi S, Sakurai Y.
    Cancer Res; 1984 Jan; 44(1):172-7. PubMed ID: 6690034
    [Abstract] [Full Text] [Related]

  • 11. In vivo studies on high-dose 1-beta-D-arabinofuranosylcytosine (HDara-C) and 1-beta-D-arabinofuranosyluracil (ara-U) with respect to pharmacokinetics, cell kinetics, and cytotoxicity in a rat myelocytic leukemia model (BNML).
    Colly LP, Willemze R, Honders W, vd Hoorn F, Edelbroek PM.
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):49-54. PubMed ID: 3859932
    [Abstract] [Full Text] [Related]

  • 12. Incorporation of N4-behenoyl-1-beta-D-arabinofuranosylcytosine into DNA as 1-beta-D-arabinofuranosylcytosine.
    Higashigawa M, Ochiai H, Ohkubo T, Kawasaki H, Nobori T, Kamiya H, Sakurai M.
    Med Oncol Tumor Pharmacother; 1988 Jun; 5(4):265-71. PubMed ID: 2848163
    [Abstract] [Full Text] [Related]

  • 13. [Clinical and pharmacokinetic studies of high dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine].
    Yoshida T, Nakamura S, Ohtake S, Ito K, Kobayashi K, Kanno M, Hirai J, Tachimori K, Matsuda T.
    Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1820-4. PubMed ID: 3592717
    [Abstract] [Full Text] [Related]

  • 14. A radioimmunoassay method for 1-beta-D-arabinofuranosyluracil using antibodies directed against 1-beta-D-arabinofuranosylcytosine.
    Okabayashi T, Mihara S, Moffatt JG.
    Cancer Res; 1977 Feb; 37(2):625-8. PubMed ID: 12864
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Experimental study on the correlation between the antitumor activity and pharmacokinetics of cytosine arabinoside (Ara-C) and N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC)].
    Takenaka T, Kimura K.
    Nihon Gan Chiryo Gakkai Shi; 1985 Dec 20; 20(10):2322-8. PubMed ID: 3831176
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.